Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

281. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association | Circulation Search for this keyword Search Search (...) for this keyword Search Header Publisher Menu AHA Scientific Statement Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association Barbara S. Wiggins , Joseph J. Saseen , Robert L. Page , Brent N. Reed , Kevin Sneed , John B. Kostis , David Lanfear , Salim Virani , Pamela B. Morris and On behalf of the American Heart Association Clinical Pharmacology

American Heart Association2016

282. 2016 Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

2016 Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult Canadian Journal of Cardiology Email/Username: Password: Remember me Search Terms Search within Search Share this page Copyright © 2018 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements on this site do

Canadian Cardiovascular Society2016

283. Prevalence and impact of diabetes, hypertension, and cardiovascular diseases in chronic obstructive pulmonary diseases: A hospital-based cross-section study

Prevalence and impact of diabetes, hypertension, and cardiovascular diseases in chronic obstructive pulmonary diseases: A hospital-based cross-section study 27847906 2018 11 13 2450-131X 3 4 2015 Oct-Dec Journal of translational internal medicine J Transl Int Med Prevalence and impact of diabetes, hypertension, and cardiovascular diseases in chronic obstructive pulmonary diseases: A hospital-based cross-section study. 155-160 Chronic obstructive pulmonary disease (COPD) is associated with (...) important chronic comorbid diseases, including diabetes, hypertension and cardiovascular diseases. As very limited data is available in India, the aim of the present study was to determine the relationship between COPD and the common, chronic comorbid conditions of diabetes mellitus (DM), hypertension (HTN), and cardiovascular diseases (CVD) and also to determine how these affect the clinical course of COPD. All the COPD cohorts diagnosed as per Global Initiative for Chronic Obstructive Lung Disease

Journal of translational internal medicine2015 Full Text: Link to full Text with Trip Pro

284. Age and Sex Specific Reference Intervals for Modifiable Risk Factors of Cardiovascular Diseases for Gujarati Asian Indians

Age and Sex Specific Reference Intervals for Modifiable Risk Factors of Cardiovascular Diseases for Gujarati Asian Indians 26824054 2016 01 29 2018 11 13 2356-6981 2015 2015 International journal of chronic diseases Int J Chronic Dis Age and Sex Specific Reference Intervals for Modifiable Risk Factors of Cardiovascular Diseases for Gujarati Asian Indians. 394798 10.1155/2015/394798 Objective. We aimed to establish age and sex specific percentile reference data for cardiovascular risk factors (...) such as lipids, sugar, blood pressure, and BMI in apparently healthy and disease-free Gujarati population. Methods. In this cross-sectional study, we enrolled 3265 apparently healthy and disease-free individuals of both genders residing in Gujarat state. Fasting samples of blood were used for biochemical estimations of lipids and sugar. The measurement of BMI and blood pressure was also done according to the standard guidelines. Age and gender specific 5th, 25th, 50th, 75th, 90th, and 95th percentiles were

International journal of chronic diseases2015 Full Text: Link to full Text with Trip Pro

285. Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease

Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease 30363519 2018 11 14 2330-1619 3 3 2016 May-Jun Movement disorders clinical practice Mov Disord Clin Pract Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease. 257-267 10.1002/mdc3.12286 Knowledge of possible cardiovascular risks from Parkinson's disease (PD) medications is critical to informing safe and effective treatment decisions. The objective of our (...) . Krewski Daniel D McLaughlin Center for Population Health Risk Assessment University of Ottawa Ottawa Ontario Canada. Risk Sciences International Ottawa Ontario Canada. eng Journal Article 2015 12 24 United States Mov Disord Clin Pract 101630279 2330-1619 Parkinson's disease cardiovascular case‐control studies cerebrovascular dopamine agonists 2015 07 13 2015 09 04 2015 09 13 2018 10 27 6 0 2015 12 24 0 0 2015 12 24 0 1 epublish 30363519 10.1002/mdc3.12286 MDC312286 PMC6178630 JAMA. 2014 Apr 23-30;311

Movement disorders clinical practice2015 Full Text: Link to full Text with Trip Pro

286. Resveratrol and Omega-3 Fatty Acid: Its Implications in Cardiovascular Diseases

Resveratrol and Omega-3 Fatty Acid: Its Implications in Cardiovascular Diseases 26697434 2015 12 23 2018 11 13 2297-055X 2 2015 Frontiers in cardiovascular medicine Front Cardiovasc Med Resveratrol and Omega-3 Fatty Acid: Its Implications in Cardiovascular Diseases. 38 10.3389/fcvm.2015.00038 The present review aims at summarizing the major therapeutic roles of resveratrol and omega-3 fatty acids (O3FAs) along with their related pathways. This article reviews some of the key studies involving (...) the health benefits of resveratrol and O3FAs. Oxidative stress has been considered as one of the most important pathophysiological factors associated with various cardiovascular disease conditions. Resveratrol, with the potent antioxidant and free radical scavenging properties, has been proven to be a significantly protective compound in restoring the normal cardiac health. A plethora of research also demonstrated the reduction of the risk of coronary heart disease, hypertension, and stroke, and

Frontiers in cardiovascular medicine2015 Full Text: Link to full Text with Trip Pro

287. Providing food to treat adolescents at risk for cardiovascular disease

Providing food to treat adolescents at risk for cardiovascular disease 26337820 2015 09 29 2016 05 05 2016 12 15 1930-739X 23 10 2015 Oct Obesity (Silver Spring, Md.) Obesity (Silver Spring) Providing food to treat adolescents at risk for cardiovascular disease. 2109-17 10.1002/oby.21246 Diet modification is recommended to treat childhood cardiovascular (CV) risk factors; however, the optimal dietary strategy is unknown. In a randomized trial, the effect of a low-fat (LF) and a low-glycemic (...) ;120(2):340-5 17671060 Adolescent Cardiovascular Diseases etiology Feeding Behavior physiology Female Food Humans Male Pediatric Obesity diet therapy Pilot Projects Risk Factors Treatment Outcome NIHMS710192 PMC4586898 2015 03 06 2015 07 07 2015 9 5 6 0 2015 9 5 6 0 2016 5 6 6 0 ppublish 26337820 10.1002/oby.21246 PMC4586898 NIHMS710192

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

288. Predicted vs Observed Clinical Event Risk for Cardiovascular Disease

Predicted vs Observed Clinical Event Risk for Cardiovascular Disease 26575068 2015 12 07 2018 12 02 1538-3598 314 19 2015 Nov 17 JAMA JAMA Predicted vs Observed Clinical Event Risk for Cardiovascular Disease-Reply. 2082-3 10.1001/jama.2015.12931 Pursnani Amit A Cardiology Division, NorthShore University Health System, Evanston, Illinois. Massaro Joseph M JM Framingham Heart Study of the National Heart, Lung, and Blood Institute, Framingham, Massachusetts. Hoffmann Udo U Cardiac MR PET CT (...) Program, Massachusetts General Hospital, Boston. eng K24 HL113128 HL NHLBI NIH HHS United States Journal Article Comment United States JAMA 7501160 0098-7484 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AIM IM JAMA. 2015 Jul 14;314(2):134-41 26172893 JAMA. 2015 Nov 17;314(19):2082 26575067 Calcinosis drug therapy Coronary Artery Disease drug therapy Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Hypercholesterolemia drug therapy Male Practice Guidelines as Topic 2015

JAMA2015 Full Text: Link to full Text with Trip Pro

289. Omega 6 fatty acids for the primary prevention of cardiovascular disease.

Omega 6 fatty acids for the primary prevention of cardiovascular disease. BACKGROUND: Omega 6 plays a vital role in many physiological functions but there is controversy concerning its effect on cardiovascular disease (CVD) risk. There is conflicting evidence whether increasing or decreasing omega 6 intake results in beneficial effects. OBJECTIVES: The two primary objectives of this Cochrane review were to determine the effectiveness of:1. Increasing omega 6 (Linoleic acid (LA), Gamma-linolenic (...) restrictions. SELECTION CRITERIA: Randomised controlled trials (RCTs) of interventions stating an intention to increase or decrease omega 6 fatty acids, lasting at least six months, and including healthy adults or adults at high risk of CVD. The comparison group was given no advice, no supplementation, a placebo, a control diet, or continued with their usual diet. The outcomes of interest were CVD clinical events (all-cause mortality, cardiovascular mortality, non-fatal end points) and CVD risk factors

Cochrane2015

290. Aspirin use to prevent cardiovascular disease and cancer: a decision analysis

Aspirin use to prevent cardiovascular disease and cancer: a decision analysis Aspirin use to prevent cardiovascular disease and cancer: a decision analysis Aspirin use to prevent cardiovascular disease and cancer: a decision analysis Dehmer SP, Maciosek MV, Flottemesch, TJ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dehmer SP (...) , Maciosek MV, Flottemesch, TJ. Aspirin use to prevent cardiovascular disease and cancer: a decision analysis. Rockville: Agency for Healthcare Research and Quality (AHRQ). AHRQ Publication No. 15-05229-EF-1. 2015 Authors' objectives To assess the net balance of benefits and harms from routine use of aspirin for primary prevention across clinically relevant age, sex, and cardiovascular disease (CVD) risk groups. Authors' conclusions Benefits are predicted to exceed harms among persons aged 40-69

Health Technology Assessment (HTA) Database.2015

291. Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system.

Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system. China has an immediate need to address the rapidly growing population with cardiovascular disease events and the increasing number of people living with this illness. Despite progress in increasing access to services, China faces the dual challenge of addressing gaps in quality of care and producing more evidence to support clinical (...) practice. In this Review, we address opportunities to strengthen performance measurement, programmes to improve quality of care, and national capacity to produce high-impact knowledge for clinical practice. Moreover, we propose recommendations, with implications for other diseases, for how China can immediately make use of its Hospital Quality-Monitoring System and other existing national platforms to assess and improve performance of medical care, and to generate new knowledge to inform clinical

Lancet2015 Full Text: Link to full Text with Trip Pro

293. Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study

Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study 26248811 2015 12 15 2016 04 07 2015 12 15 1462-0332 55 1 2016 Jan Rheumatology (Oxford, England) Rheumatology (Oxford) Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study. 33-40 10.1093/rheumatology/kev262 To determine the risk of newly recorded myocardial infarction (MI) and stroke among incident GCA cases compared with controls from the general (...) provide general population-based evidence that GCA patients are at a substantially increased risk of cardiovascular disease. Increased monitoring for this potentially fatal outcome and its modifiable risk factors is warranted for GCA patients. © The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com. Amiri Neda N Division of Rheumatology, Department of Medicine, University

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

294. The relationship between psychosocial risk factors and health outcomes of chronic diseases: a review of the evidence for cancer and cardiovascular diseases

The relationship between psychosocial risk factors and health outcomes of chronic diseases: a review of the evidence for cancer and cardiovascular diseases The relationship between psychosocial risk factors and health outcomes of chronic diseases: a review of the evidence for cancer and cardiovascular diseases HEALTH EVIDENCE NETWORK SYNTHESIS REPORT Hynek Pikhart | Jitka PikhartovaThe Health Evidence Network HEN – the Health Evidence Network – is an information service for public health (...) Network synthesis report The relationship between psychosocial risk factors and health outcomes of chronic diseases: a review of the evidence for cancer and cardiovascular diseases Hynek Pikhart | Jitka PikhartovaAbstract This report summarizes the best available evidence for a link between psychosocial factors and cardiovascular and cancer morbidity and mortality in Europe. A total of 1822 Medline and PubMed articles published in English since January 2000 were searched, identifying 37 systematic

WHO Health Evidence Network2015

295. Vitamin K for the primary prevention of cardiovascular disease.

Vitamin K for the primary prevention of cardiovascular disease. BACKGROUND: A deficiency in vitamin K has been associated with increased calcium deposition and coronary artery calcification, which may lead to cardiovascular disease. OBJECTIVES: To determine the effectiveness of vitamin K supplementation as a single nutrient supplement for the primary prevention of cardiovascular disease. SEARCH METHODS: We searched the following electronic databases: the Cochrane Central Register of Controlled (...) and reference lists of reviews for further studies. We applied no language restrictions. SELECTION CRITERIA: We included randomised controlled trials of vitamin K supplementation as a single nutrient supplement, lasting at least three months, and involving healthy adults or adults at high risk of cardiovascular disease. The comparison group was no intervention or placebo. The outcomes of interest were cardiovascular disease clinical events and cardiovascular disease risk factors. DATA COLLECTION

Cochrane2015

296. Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study.

Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study. BACKGROUND: Alcohol consumption is proposed to be the third most important modifiable risk factor for death and disability. However, alcohol consumption has been associated with both benefits and harms, and previous studies were mostly done in high-income countries. We investigated associations between alcohol consumption and outcomes in a prospective cohort (...) of countries at different economic levels in five continents. METHODS: We included information from 12 countries participating in the Prospective Urban Rural Epidemiological (PURE) study, a prospective cohort study of individuals aged 35-70 years. We used Cox proportional hazards regression to study associations with mortality (n=2723), cardiovascular disease (n=2742), myocardial infarction (n=979), stroke (n=817), alcohol-related cancer (n=764), injury (n=824), admission to hospital (n=8786

Lancet2015

297. A prospective multicentre study on the treatment of cardiovascular risk factors and claudication symptoms in patients with peripheral artery disease (the IDOMENEO study).

A prospective multicentre study on the treatment of cardiovascular risk factors and claudication symptoms in patients with peripheral artery disease (the IDOMENEO study). 26317257 2015 08 31 2015 10 27 2015 08 31 0301-1526 44 5 2015 Sep VASA. Zeitschrift fur Gefasskrankheiten VASA A prospective multicentre study on the treatment of cardiovascular risk factors and claudication symptoms in patients with peripheral artery disease (the IDOMENEO study). 371-9 10.1024/0301-1526/a000456 The objective (...) of this prospective multicenter cohort study was to characterise the use of pharmacological and non-pharmacological treatment for cardiovascular disease (CVD) risk factors and intermittent claudication (IC) symptoms in clinical practice patients with peripheral artery disease (PAD), and to determine the care gap with international guidelines and evidence-based therapy. From 2011 through 2013, participating centres enrolled consecutive patients with PAD of atherosclerotic, origin demonstrated by ultrasound, ankle

VASA. Zeitschrift fur Gefasskrankheiten2015 Full Text: Link to full Text with Trip Pro

298. Prognostic Value of Stress Echocardiography in Patients With Low-Intermediate or High Short-Term (10 Years) Versus Low (</=39%) or High (>/=39%) Lifetime Predicted Risk of Cardiovascular Disease According to the American College of Cardiology/American Hea

Prognostic Value of Stress Echocardiography in Patients With Low-Intermediate or High Short-Term (10 Years) Versus Low (/=39%) Lifetime Predicted Risk of Cardiovascular Disease According to the American College of Cardiology/American Hea 26138377 2015 08 15 2015 11 10 2016 11 25 1879-1913 116 5 2015 Sep 01 The American journal of cardiology Am. J. Cardiol. Prognostic Value of Stress Echocardiography in Patients With Low-Intermediate or High Short-Term (10 Years) Versus Low (...) (<39%) or High (≥39%) Lifetime Predicted Risk of Cardiovascular Disease According to the American College of Cardiology/American Heart Association 2013 Cardiovascular Risk Calculator. 725-9 10.1016/j.amjcard.2015.05.040 S0002-9149(15)01424-1 This study evaluates the prognostic value of stress echocardiography (Secho) in short-term (10 years) and lifetime atherosclerotic cardiovascular disease risk-defined groups according to the American College of Cardiology/American Heart Association 2013

EvidenceUpdates2015

299. Qigong for the primary prevention of cardiovascular disease.

Qigong for the primary prevention of cardiovascular disease. BACKGROUND: Two major determinants of cardiovascular disease (CVD) are a sedentary lifestyle and stress. Qigong involves physical exercise, mind regulation and breathing control to restore the flow of Qi (a pivotal life energy). As it is thought to help reduce stress and involves exercise, qigong may be an effective strategy for the primary prevention of CVD. OBJECTIVES: To determine the effectiveness of qigong for the primary

Cochrane2015

300. Cangrelor (Kengraxel) - for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention

Cangrelor (Kengraxel) - for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention Published 08 June 2015 Statement of Advice cangrelor (Kengrexal ® ) SMC No. (1070/15) The Medicines Company 08 May 2015 ADVICE: in the absence of a submission from the holder of the marketing authorisation cangrelor (Kengrexal ® ) is not recommended for use within NHS Scotland. Indication under review: Co-administered (...) with acetylsalicylic acid for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context

Scottish Medicines Consortium2015